Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model Takafumi YamamotoFumiko ArakawaMasahide Kuroki ORIGINAL ARTICLE Pages: 165 - 171
Efficacy of repeated cycles of chemo-immunotherapy with Thymosin α1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery Gianfranco SilecchiaEnrico GuarinoGuido Rasi ORIGINAL ARTICLE Pages: 172 - 178
Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: in vitro and in vivo studies Benny LeshemYael DorfmanEli Kedar ORIGINAL ARTICLE Pages: 179 - 188
Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide Tatsuo FujieFumiaki TanakaTsuyoshi Akiyoshi ORIGINAL ARTICLE Pages: 189 - 194
Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex Ursula GrohmannMaria Laura BelladonnaPaolo Puccetti ORIGINAL ARTICLE Pages: 195 - 203
Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+renal-cell-carcinoma-infiltrating lymphocytes Ursula Elsässer-BeileThomas GrussenmeyerJürgen Schulte Mönting ORIGINAL ARTICLE Pages: 204 - 208
Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity C. LehmannB. GlassL. Uharek ORIGINAL ARTICLE Pages: 209 - 213
Prerequisites for the Immunotherapy of Cancer Graham PawelecAndrea EngelMedi Adibzadeh SYMPOSIUM SERIES Pages: 214 - 217
